Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study

The addition of sildenafil to nintedanib treatment does not improve outcomes to a greater extent than monotherapy with nintedanib, and it is not recommended for IPF subjects 
http://ow.ly/Gaq530o9kEg

Detalles Bibliográficos
Autores principales: Suarez-Cuartin, Guillermo, Molina-Molina, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544796/
https://www.ncbi.nlm.nih.gov/pubmed/31191729
http://dx.doi.org/10.1183/20734735.0016-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544796/
https://www.ncbi.nlm.nih.gov/pubmed/31191729
http://dx.doi.org/10.1183/20734735.0016-2019

Ejemplares similares